This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Kisspeptin in Hypoactive Sexual Desire Disorder (HSDD) in men

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Kisspeptin in Hypoactive Sexual Desire Disorde (HSDD)

  • neuropeptide kisspeptin is a crucial endogenous activator of the reproductive system, with extensive distribution throughout the rodent and human brain (1)
    • is known that kisspeptin, acting centrally via the kisspeptin receptor, stimulates secretion of gonadotrophin releasing hormone (GnRH)
    • loss of kisspeptin signaling causes hypogonadotrophic hypogonadism in humans and other mammals (2)
      • kisspeptin interacts with other neuropeptides such as neurokinin B and dynorphin, to regulate GnRH pulse generation
    • evidence from animal models reveals that kisspeptin signaling has key roles in modulating reproductive behavior, including sexual motivation and erections (1)
      • evidence shows that kisspeptin administration substantially modulates sexual brain processing in men with Hypoactive Sexual Desire Disorde (HSDD), with associated increases in penile tumescence and behavioral measures of sexual desire and arousal (1)

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.